331 related articles for article (PubMed ID: 25363438)
1. Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer.
Chalmer T; Almdal TP; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2015 Jan; 14(1):171-80. PubMed ID: 25363438
[TBL] [Abstract][Full Text] [Related]
2. Emerging GLP-1 receptor agonists.
Lund A; Knop FK; Vilsbøll T
Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
[TBL] [Abstract][Full Text] [Related]
3. Liraglutide (Victoza) for type 2 diabetes.
Med Lett Drugs Ther; 2010 Apr; 52(1335):25-7. PubMed ID: 20360660
[TBL] [Abstract][Full Text] [Related]
4. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.
Alves C; Batel-Marques F; Macedo AF
Diabetes Res Clin Pract; 2012 Nov; 98(2):271-84. PubMed ID: 23010561
[TBL] [Abstract][Full Text] [Related]
5. An overview of the pharmacokinetics, efficacy and safety of liraglutide.
Bode B
Diabetes Res Clin Pract; 2012 Jul; 97(1):27-42. PubMed ID: 22245694
[TBL] [Abstract][Full Text] [Related]
6. GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.
Jespersen MJ; Knop FK; Christensen M
Expert Opin Drug Metab Toxicol; 2013 Jan; 9(1):17-29. PubMed ID: 23094590
[TBL] [Abstract][Full Text] [Related]
7. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
Montanya E; Sesti G
Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.
Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
Diabetes Res Clin Pract; 2014 Feb; 103(2):269-75. PubMed ID: 24485345
[TBL] [Abstract][Full Text] [Related]
9. Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
Ryan GJ; Hardy Y
J Clin Pharm Ther; 2011 Jun; 36(3):260-74. PubMed ID: 21545609
[TBL] [Abstract][Full Text] [Related]
10. Liraglutide in type 2 diabetes mellitus.
Baruah MP; Chaudhury T; Sethi BK; Dharmalingam M
J Indian Med Assoc; 2012 May; 110(5):335-8. PubMed ID: 23360033
[TBL] [Abstract][Full Text] [Related]
11. Clinical pearls for initiating and utilizing liraglutide in patients with type 2 diabetes.
Gross B
J Pharm Pract; 2013 Apr; 26(2):144-50. PubMed ID: 23204146
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide: a new treatment for type 2 diabetes.
Vilsboll T
Drugs Today (Barc); 2009 Feb; 45(2):101-13. PubMed ID: 19343230
[TBL] [Abstract][Full Text] [Related]
13. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
14. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
Moon HS; Kim MK; Son MH
Arch Pharm Res; 2011 Jul; 34(7):1041-3. PubMed ID: 21811909
[TBL] [Abstract][Full Text] [Related]
15. Liraglutide-induced acute pancreatitis.
Jeyaraj S; Shetty AS; Kumar CR; Nanditha A; Krishnamoorthy S; Raghavan A; Raghavan K; Ramachandran A
J Assoc Physicians India; 2014 Jan; 62(1):64-6. PubMed ID: 25327099
[TBL] [Abstract][Full Text] [Related]
16. Pancreatitis: a potential complication of liraglutide?
Franks AS; Lee PH; George CM
Ann Pharmacother; 2012 Nov; 46(11):1547-53. PubMed ID: 23136352
[TBL] [Abstract][Full Text] [Related]
17. Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner.
Zhao H; Wei R; Wang L; Tian Q; Tao M; Ke J; Liu Y; Hou W; Zhang L; Yang J; Hong T
Am J Physiol Endocrinol Metab; 2014 Jun; 306(12):E1431-41. PubMed ID: 24801389
[TBL] [Abstract][Full Text] [Related]
18. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
19. [Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide].
Reboldi G
G Ital Cardiol (Rome); 2009 Jul; 10(7):434-47. PubMed ID: 19761101
[TBL] [Abstract][Full Text] [Related]
20. Next-generation GLP-1 therapy: an introduction to liraglutide.
Repas T
Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
